Zhejiang Wecome Pharmaceutical 관리

관리 기준 확인 3/4

Zhejiang Wecome Pharmaceutical CEO는 Xiaoxia Kong, May2021 에 임명되었습니다 의 임기는 3.5 년입니다. 는 CN¥ 16.61M 가치에 해당하는 회사 주식의 0.63% 직접 소유합니다. 16.61M. 경영진과 이사회의 평균 재임 기간은 각각 3.5 년과 3.5 년입니다.

주요 정보

Xiaoxia Kong

최고 경영자

CN¥1.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	3.5yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

Subdued Growth No Barrier To Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) With Shares Advancing 39%

Oct 09

Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) Investors Are Less Pessimistic Than Expected

Aug 02

Subdued Growth No Barrier To Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) With Shares Advancing 29%

Mar 08

CEO

Xiaoxia Kong (42 yo)

3.5yrs

테뉴어

CN¥1,001,900

보상

Ms. Xiaoxia Kong serves as General Manager at Zhejiang Wecome Pharmaceutical Company Limited since May 17, 2021 and has been its Director since May 17, 2021 and was its Deputy General Manager until May 17,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Xiaoxia Kong	GM & Director	3.5yrs	CN¥1.00m	0.63% CN¥ 16.6m
Jing Wang	Finance Director	3.5yrs	CN¥219.60k	데이터 없음
Jianming Wu	Deputy GM & Non-Independent Director	3.5yrs	CN¥299.80k	데이터 없음
Ting Zhu	Secretary & Non-Independent Director	3.5yrs	CN¥219.90k	데이터 없음
Dexiong Dai	Deputy General Manager	9.7yrs	CN¥266.90k	0.25% CN¥ 6.5m
Jingwei Ding	Deputy General Manager	3.5yrs	CN¥269.10k	데이터 없음

3.5yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: 300878 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xiaoxia Kong	GM & Director	3.5yrs	CN¥1.00m	0.63% CN¥ 16.6m
Jianming Wu	Deputy GM & Non-Independent Director	3.5yrs	CN¥299.80k	데이터 없음
Ting Zhu	Secretary & Non-Independent Director	3.5yrs	CN¥219.90k	데이터 없음
Bin Wu	Independent Director	2.1yrs	CN¥80.00k	데이터 없음
Zhongliang Liu	Chairman of the Board	9.7yrs	CN¥980.00k	69.01% CN¥ 1.8b
Ping Ye	Chairman of the Supervisory Board	9.7yrs	데이터 없음	데이터 없음
Xiaohong Yu	Non-Employee Supervisor	8.8yrs	데이터 없음	데이터 없음
Jiangfeng Liu	Independent Director	3.5yrs	CN¥80.00k	데이터 없음
Caihong Shen	Supervisor	9.7yrs	데이터 없음	데이터 없음
Lan Hao	Independent Director	3.5yrs	CN¥80.00k	데이터 없음

3.5yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 이사회: 300878 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Zhejiang Wecome Pharmaceutical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Zhejiang Wecome Pharmaceutical Company Limited, Annual General Meeting, May 20, 2024

High number of new directors

High number of new and inexperienced directors

Recent updates

New minor risk - Share price stability

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.033 in 3Q 2023)

Subdued Growth No Barrier To Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) With Shares Advancing 39%

New minor risk - Share price stability

Zhejiang Wecome Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 28, 2024

Second quarter 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.26 profit in 2Q 2023)

Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) Investors Are Less Pessimistic Than Expected

Zhejiang Wecome Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Dividend sustainability

First quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.19 in 1Q 2023)

Zhejiang Wecome Pharmaceutical Company Limited, Annual General Meeting, May 20, 2024

Zhejiang Wecome Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Subdued Growth No Barrier To Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) With Shares Advancing 29%

Zhejiang Wecome Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.033 (vs CN¥0.26 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.24 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.16 in 1Q 2022)

Investor sentiment improved over the past week

High number of new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2021)

Investor sentiment deteriorated over the past week

Zhejiang Wecome Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 17 June 2022

Zhejiang Wecome Pharmaceutical Company Limited Approved Cash Dividend for the Year 2021

Zhejiang Wecome Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.25 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.39 in 3Q 2020)

An unknown buyer completed the acquisition of 70% stake in Zhejiang Wecome Printing Co., Ltd. from Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878).

Second quarter 2021 earnings released: EPS CN¥0.54 (vs CN¥0.39 in 2Q 2020)

Investor sentiment improved over the past week

Zhejiang Wecome Pharmaceutical Company Limited Announces Cash Dividend, Payable on 31 May 2021

Zhejiang Wecome Pharmaceutical Company Limited Approves Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.71 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.03 (vs CN¥2.09 in FY 2019)

Zhejiang Wecome Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥48.67

New 90-day low: CN¥57.50

Third quarter earnings released

Market bids up stock over the past week

Market bids up stock over the past week

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령